Goldman Sachs initiated coverage of Enliven with a Not Rated rating. Enliven is a small-molecule precision oncology company leveraging differentiated chemistry against validated biological targets, the analyst tells investors in a research note. The firm says preclinical data for the BCR-ABL-targeting tyrosine kinase inhibitor ELVN-001 suggests a potent and tolerable profile in chronic myelogenous leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
